The board of directors of the China Isotope & Radiation Corporation announced that, on August 13, 2020, the company and Nuclear Industry Hospital entered into a strategic cooperation framework agreement. Pursuant to the agreement, both parties would commence in-depth cooperation in terms of disciplines establishment, technology innovation, talents nurturing and international cooperation with an aim to accomplish mutual benefits and joint development by putting the advantages of both parties into full play. Leveraging on its advantages, CIRC will proactively participate in the construction of the "nuclide diagnostic center" and the "nuclear technology clinical research center" newly established by Nuclear Industry Hospital. Both parties will cooperate to make researches and breakthroughs in areas such as new nuclide diagnosis products and technologies as well as clinical application and conversion of nuclear technology, thereby jointly enhancing the overall level of nuclear technology application and nuclear medication in the PRC. As a class III grade A hospital integrating the functions of medication, education, scientific researches, prevention and nuclear emergency response, Nuclear Industry Hospital is a State Clinical Trial Base, a State Hospitalist Standardised Training Base, a State Nuclear Emergency Medical Rescue Base, a State Stroke Center and a National Chest Pain Center. Nuclear Industry Hospital possesses a State Key Laboratory of Radiation Medicine and Protection, a Radiation Medicine and Conversion Center, 7 key laboratories at municipal level, 4 university clinical trial research institutes as well as a platform for domestic multi-center cooperation, while having extensive cooperation with France, the United States, Japan and Israel. CIRC is a subsidiary of China National Nuclear Corporation specialising in nuclear technology application with business coverage including production of radioactive source, production of radioactive medicine, industrial nuclear applications, medical diagnosis, research and development/services of nuclear medical devices, production of nuclides and import and export trading. Through the cooperation, both parties join force and open access to the frontline and application industry chain of nuclear medication in terms of nuclear technology application. By establishing an integrated clinical platform, being a domestically top-notch and internationally renowned nuclear technology medication application foundation, it offers an essential support to the Company for nuclear technology application in terms of talents nurturing, technological innovation and industry development. Both parties could attain complementarities and innovation, while establish a center leading innovation and radiative development with considerable influence, and hence representing a new driving force for quality development of nuclear technology application industries. Entering into the strategic cooperation framework agreement does not constitute a notifiable transaction under Chapter 14 and a connected transaction under Chapter 14A of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.